New antibody cocktail aimed at MDS shows early promise, but study halted
NCT ID NCT04810611
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested combinations of three antibody drugs (sabatolimab, NIS793, and canakinumab) in 33 adults with lower-risk myelodysplastic syndrome (MDS), a blood disorder. The main goal was to check safety and find the right doses. The study was terminated early, so its findings are limited, but it aimed to reduce the need for blood transfusions in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sabatolimab, NIS793, and canakinumab (antibody drugs targeting immune signals)
What this could lead to
If successful, this could point toward new drug combinations to manage lower-risk MDS and reduce the need for blood transfusions.
What could go wrong
This was a very early (phase 1) study with only 33 participants, and it was terminated early, so results are limited. The drugs may not prove effective or safe in larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City Of Hope National Med Center Oncology
Duarte, California, 91010, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
MD Anderson Cancer Center/University of Texas MD Anderson
Houston, Texas, 77030, United States
-
Massachusetts General Hospital .
Boston, Massachusetts, 02114, United States
-
Novartis Investigative Site
Prahran, Victoria, 3181, Australia
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Singapore, 119228, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Novartis Investigative Site
Seoul, 03080, South Korea
-
Novartis Investigative Site
Salamanca, Castille and León, 37007, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
The Ohio State University Wexner Medical Center .
Columbus, Ohio, 43210, United States